Related Experiment Video
Updated: Jun 12, 2026

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Effects of fumonisin B1 on HLA class I antigen presentation and processing pathway in GES-1 cells in vitro
1Laboratory of Pathology, Hebei Medical University, Shijiazhuang, Hebei, China.
Abstract:
Fumonisin B1 (FB1) is a food-borne mycotoxin produced by genus Fusarium and was classified as possible carcinogen to humans by the International Agency for Research on Cancer (IARC). Human leukocyte antigen (HLA) class I antigen presentation pathway plays an important role in immunosurveillance. Defects in HLA class I antigen presentation pathway can down-regulate the expression of HLA class I antigen on the surface of nucleated cells that will confer a survival advantage to randomly mutant cells and may lead to malignant transformation. In the present study, we analyzed the effects of FB1 on the expression of HLA class I heavy chain (classical HLA-A, -B and -C genes included), beta2-microglobulin (β2m), LMP2 and TAP1 genes in human gastric epithelial immortalized GES-1 cells in vitro using semi-quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR), Western blot and immunocytochemical methods in dose- and time-effect studies. Our results revealed that FB1 have an effect on HLA class I antigen presentation pathway via the decreased expression of HLA class I heavy chain and/or defects of LMP2 and TAP1 expression. However, the importance of this effect in carcinogenesis needs further investigation.
More Related Videos
10:01Quantification of Fungal Colonization, Sporogenesis, and Production of Mycotoxins Using Kernel Bioassays
Published on: April 23, 2012
09:21Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.
Published on: February 15, 2019
Related Concept Videos
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.